Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.18
NAS:DEPO's Cash-to-Debt is ranked lower than
87% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NAS:DEPO: 0.18 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:DEPO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 10.14 Max: No Debt
Current: 0.18
Equity-to-Asset 0.19
NAS:DEPO's Equity-to-Asset is ranked lower than
93% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:DEPO: 0.19 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:DEPO' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.34 Max: 0.97
Current: 0.19
-2.63
0.97
Debt-to-Equity 3.19
NAS:DEPO's Debt-to-Equity is ranked lower than
97% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NAS:DEPO: 3.19 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:DEPO' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.32  Med: 0.36 Max: 5.13
Current: 3.19
-8.32
5.13
Debt-to-EBITDA 5.81
NAS:DEPO's Debt-to-EBITDA is ranked lower than
82% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. NAS:DEPO: 5.81 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:DEPO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.67  Med: 0.68 Max: 22.27
Current: 5.81
-0.67
22.27
Interest Coverage 0.11
NAS:DEPO's Interest Coverage is ranked lower than
100% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. NAS:DEPO: 0.11 )
Ranked among companies with meaningful Interest Coverage only.
NAS:DEPO' s Interest Coverage Range Over the Past 10 Years
Min: 0.11  Med: 8.12 Max: No Debt
Current: 0.11
Piotroski F-Score: 5
Altman Z-Score: 0.37
Beneish M-Score: -3.40
WACC vs ROIC
9.48%
40.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 2.05
NAS:DEPO's Operating Margin % is ranked lower than
67% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NAS:DEPO: 2.05 )
Ranked among companies with meaningful Operating Margin % only.
NAS:DEPO' s Operating Margin % Range Over the Past 10 Years
Min: -49.06  Med: 4.94 Max: 72.49
Current: 2.05
-49.06
72.49
Net Margin % -27.73
NAS:DEPO's Net Margin % is ranked lower than
81% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. NAS:DEPO: -27.73 )
Ranked among companies with meaningful Net Margin % only.
NAS:DEPO' s Net Margin % Range Over the Past 10 Years
Min: -43.92  Med: -7.32 Max: 75.05
Current: -27.73
-43.92
75.05
ROE % -48.13
NAS:DEPO's ROE % is ranked lower than
85% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. NAS:DEPO: -48.13 )
Ranked among companies with meaningful ROE % only.
NAS:DEPO' s ROE % Range Over the Past 10 Years
Min: -90.05  Med: -1.11 Max: 532.43
Current: -48.13
-90.05
532.43
ROA % -9.81
NAS:DEPO's ROA % is ranked lower than
76% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. NAS:DEPO: -9.81 )
Ranked among companies with meaningful ROA % only.
NAS:DEPO' s ROA % Range Over the Past 10 Years
Min: -23.58  Med: -1.26 Max: 73.87
Current: -9.81
-23.58
73.87
ROC (Joel Greenblatt) % 25.43
NAS:DEPO's ROC (Joel Greenblatt) % is ranked higher than
68% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. NAS:DEPO: 25.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:DEPO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2282.52  Med: 123.58 Max: 8060.52
Current: 25.43
-2282.52
8060.52
3-Year Revenue Growth Rate 47.20
NAS:DEPO's 3-Year Revenue Growth Rate is ranked higher than
97% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NAS:DEPO: 47.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:DEPO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -74.4  Med: 39.55 Max: 517.8
Current: 47.2
-74.4
517.8
3-Year EBITDA Growth Rate 95.70
NAS:DEPO's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NAS:DEPO: 95.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:DEPO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.3  Med: 7.6 Max: 95.7
Current: 95.7
-55.3
95.7
GuruFocus has detected 3 Warning Signs with Depomed Inc NAS:DEPO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:DEPO's 30-Y Financials

Financials (Next Earnings Date: 2018-02-21)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

DEPO Guru Trades in Q4 2016

Mario Gabelli 15,000 sh (New)
Jeremy Grantham 256,509 sh (+150.74%)
John Hussman 150,000 sh (+50.00%)
Jeremy Grantham 500,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q1 2017

DEPO Guru Trades in Q1 2017

Jim Simons 218,438 sh (New)
Paul Tudor Jones 19,800 sh (New)
Joel Greenblatt 60,893 sh (New)
Mario Gabelli 47,000 sh (+213.33%)
John Hussman 304,200 sh (+102.80%)
Jeremy Grantham Sold Out
» More
Q2 2017

DEPO Guru Trades in Q2 2017

Discovery Group I, LLC 1,658,826 sh (New)
Mario Gabelli 55,000 sh (+17.02%)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons 198,438 sh (-9.16%)
John Hussman 150,000 sh (-50.69%)
» More
Q3 2017

DEPO Guru Trades in Q3 2017

Jim Simons 1,019,200 sh (+413.61%)
Discovery Group I, LLC Sold Out
Mario Gabelli 38,000 sh (-30.91%)
John Hussman 50,000 sh (-66.67%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-09-30 Reduce -30.91%$5.64 - $11.02 $ 6.30-21%38,000
Mario Gabelli 2017-06-30 Add 17.02%$9.5 - $13.75 $ 6.30-43%55,000
Joel Greenblatt 2017-06-30 Sold Out 0.01%$9.5 - $13.75 $ 6.30-43%0
Joel Greenblatt 2017-03-31 New Buy0.01%$12.55 - $21.31 $ 6.30-63%60,893
Mario Gabelli 2017-03-31 Add 213.33%$12.55 - $21.31 $ 6.30-63%47,000
Mario Gabelli 2016-12-31 New Buy$17.59 - $26.01 $ 6.30-70%15,000
Joel Greenblatt 2016-12-31 Sold Out 0.03%$17.59 - $26.01 $ 6.30-70%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:TLGT, NAS:TTPH, NAS:PETQ, NAS:COLL, NAS:ACET, TSE:4577, LSE:BMK, TSE:4517, BOM:500126, NAS:NEOS, XKRX:002250, NAS:AQXP, XKRX:008490, NZSE:CVT, NAS:SNDX, XKRX:183490, TPE:3705, TSE:4597, XKRX:234080, XKRX:214390 » details
Traded in other countries:DPO.Germany,
Headquarter Location:USA
Depomed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Depomed is a specialty and generic drug manufacturer. The company is focused on pain and central nervous system conditions. Depomed operates solely in the United States. It also has recognized license and royalty revenue from license agreements in the territories of the U.S., Canada, and Korea. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Depomed Inc

Depomed to Participate at the Annual Piper Jaffray Healthcare Conference
Depomed to Participate at the Annual Piper Jaffray Healthcare Conference
Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions
Depomed to Report Third Quarter 2017 Financial Results on Tuesday, November 7, 2017
Depomed Announces Appointment of Santosh J. Vetticaden, M.D., PH.D. as Senior Vice President, Chief Medical and Scientific Officer
EQUITY ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses Exceeding $500,000 to Contact the Firm
Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Depomed, Inc. (DEPO)
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 – DEPO
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed, Inc. - DEPO

Ratios

vs
industry
vs
history
Forward PE Ratio 10.46
DEPO's Forward PE Ratio is ranked higher than
91% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. DEPO: 10.46 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 11.10
DEPO's Price-to-Owner-Earnings is ranked higher than
93% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. DEPO: 11.10 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DEPO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.68  Med: 8.61 Max: 212
Current: 11.1
2.68
212
PB Ratio 2.00
DEPO's PB Ratio is ranked higher than
71% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. DEPO: 2.00 )
Ranked among companies with meaningful PB Ratio only.
DEPO' s PB Ratio Range Over the Past 10 Years
Min: 1.55  Med: 4.15 Max: 22.64
Current: 2
1.55
22.64
PS Ratio 0.93
DEPO's PS Ratio is ranked higher than
85% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. DEPO: 0.93 )
Ranked among companies with meaningful PS Ratio only.
DEPO' s PS Ratio Range Over the Past 10 Years
Min: 0.74  Med: 3.13 Max: 17.9
Current: 0.93
0.74
17.9
Price-to-Free-Cash-Flow 5.62
DEPO's Price-to-Free-Cash-Flow is ranked higher than
96% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. DEPO: 5.62 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DEPO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.37  Med: 10.3 Max: 291.05
Current: 5.62
2.37
291.05
Price-to-Operating-Cash-Flow 5.57
DEPO's Price-to-Operating-Cash-Flow is ranked higher than
95% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. DEPO: 5.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DEPO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.35  Med: 10.03 Max: 271.08
Current: 5.57
2.35
271.08
EV-to-EBIT 240.02
DEPO's EV-to-EBIT is ranked lower than
98% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. DEPO: 240.02 )
Ranked among companies with meaningful EV-to-EBIT only.
DEPO' s EV-to-EBIT Range Over the Past 10 Years
Min: -302.2  Med: -0.5 Max: 309.7
Current: 240.02
-302.2
309.7
EV-to-EBITDA 8.43
DEPO's EV-to-EBITDA is ranked higher than
84% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. DEPO: 8.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
DEPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -582.9  Med: 2.7 Max: 124.5
Current: 8.43
-582.9
124.5
EV-to-Revenue 2.21
DEPO's EV-to-Revenue is ranked higher than
64% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. DEPO: 2.21 )
Ranked among companies with meaningful EV-to-Revenue only.
DEPO' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 2.8 Max: 16
Current: 2.21
0.2
16
Current Ratio 0.83
DEPO's Current Ratio is ranked lower than
94% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. DEPO: 0.83 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s Current Ratio Range Over the Past 10 Years
Min: 0.29  Med: 2.76 Max: 56
Current: 0.83
0.29
56
Quick Ratio 0.79
DEPO's Quick Ratio is ranked lower than
87% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. DEPO: 0.79 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.29  Med: 2.67 Max: 56
Current: 0.79
0.29
56
Days Inventory 53.75
DEPO's Days Inventory is ranked higher than
85% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. DEPO: 53.75 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s Days Inventory Range Over the Past 10 Years
Min: 49.12  Med: 208.69 Max: 544.34
Current: 53.75
49.12
544.34
Days Sales Outstanding 68.68
DEPO's Days Sales Outstanding is ranked higher than
56% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. DEPO: 68.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.13  Med: 29.91 Max: 81.71
Current: 68.68
12.13
81.71
Days Payable 33.10
DEPO's Days Payable is ranked lower than
61% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. DEPO: 33.10 )
Ranked among companies with meaningful Days Payable only.
DEPO' s Days Payable Range Over the Past 10 Years
Min: 30.8  Med: 91.87 Max: 159.38
Current: 33.1
30.8
159.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.60
DEPO's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. DEPO: -2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DEPO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.9  Med: -7.55 Max: -2.2
Current: -2.6
-58.9
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.79
DEPO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
89% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. DEPO: 0.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DEPO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.71  Med: 2.2 Max: 335
Current: 0.79
0.71
335
Price-to-Median-PS-Value 0.31
DEPO's Price-to-Median-PS-Value is ranked higher than
96% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. DEPO: 0.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DEPO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.75 Max: 394
Current: 0.31
0.27
394
Earnings Yield (Greenblatt) % 0.42
DEPO's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. DEPO: 0.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DEPO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -213.8  Med: -0.3 Max: 266.4
Current: 0.42
-213.8
266.4

More Statistics

Revenue (TTM) (Mil) $410.23
EPS (TTM) $ -1.83
Beta0.70
Short Percentage of Float20.61%
52-Week Range $4.31 - 21.38
Shares Outstanding (Mil)63.01

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 389 398 433
EPS ($) 0.42 0.59 0.74
EPS without NRI ($) 0.42 0.59 0.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}